P17-17. Newborn mice vaccination with rBCG:HIVA + MVA:HIVA enhances HIV-1-specific immune responses. Influence of age and immunization routes

N. Saubi, E. Im, R. Fernandez-Lloris, O. Gil, P. Cardona, J. Gatell, T. Hanke, J. Joseph*

*Autor corresponent d’aquest treball

Producció científica: Contribució a revistaArticleRecercaAvaluat per experts

Resum

It has been demonstrated by several groups that the use of rBCG expressing HIV immunogens is a good priming vector for vaccinia based HIV vaccines, mainly in the prevention of mother-to-child HIV transmission. Our group has shown in Balb/C mice that rBCG:HIVA can both prime novel and boost preexisting HIV-1 specific cellular immune responses. In this study we have evaluated the HIV specific cellular immune responses induced after newborn and adult mice immunization using different routes with rBCG:HIVA prime and MVA:HIVA boost
Idioma originalAnglès
Número d’article1742
Pàgines (de-a)P299
Nombre de pàgines1
RevistaRetrovirology
Volum6
NúmeroSUPPL. 3
DOIs
Estat de la publicacióPublicada - 22 d’oct. 2009

Fingerprint

Navegar pels temes de recerca de 'P17-17. Newborn mice vaccination with rBCG:HIVA + MVA:HIVA enhances HIV-1-specific immune responses. Influence of age and immunization routes'. Junts formen un fingerprint únic.

Com citar-ho